That's why there are clinical trial with Allo CAR-T and the current result look a lot more promising then Auto CAR-T where around 60% fail these treatment. Of course providing a generic off the shelf drug is easier to manufacture so a lot more cost effective than manufacturing a drug from cell of each individual patient.
IMU Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)